RE: Pyc11 Feb 2022 13:51
'Physiomics will receive a fee (capped at £6m) of 6% of any future net revenues that may be received by ValiRx relating to its commercialisation of VAL201 and its derivatives in any indication, including prostate cancer, endometriosis and treatment for Coronavirus infection.'
In the presentation suzy mentioned acquiring a lab with contracts and revenues already in place, id love it to be pyc. We'd earn back the 6m we've entitled them to, their contracts are with Merck as well so wed have a foot in the door to license val 401 to them. I might just be getting over excited!